Trevi Therapeutics, Inc.
TRVIDrugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
2dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
TRVI Earnings Report
EPS Est: $-0.11 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
How TRVI's past catalysts played out
Nalbuphine ER Tablets
Prurigo Nodularis
nalbuphine HCl ER tablets 90 mg BID
Prurigo Nodularis
nalbuphine HCl ER tablets 60 mg BID
Uremic Pruritus
nalbuphine HCl ER
Uremic Pruritus
NAL ER
Refractory Chronic Cough
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nalbuphine ER Tablets | Phase 3 | Prurigo Nodularis | - | - |
nalbuphine HCl ER tablets 90 mg BID | Phase 3 | Prurigo Nodularis | - | - |
nalbuphine HCl ER tablets 60 mg BID | Phase 3 | Uremic Pruritus | - | - |
nalbuphine HCl ER | Phase 3 | Uremic Pruritus | - | - |
NAL ER | Phase 2 | Refractory Chronic Cough | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Trevi Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Trevi Therapeutics, Inc.'s (TRVI) pipeline across Phase 3, Phase 2. Its lead program is Nalbuphine ER Tablets (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Trevi Therapeutics, Inc.'s next FDA catalyst?→
Trevi Therapeutics, Inc.'s (TRVI) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TRVI biotech catalysts?→
Add TRVI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Trevi Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.